Helm AG is a Hamburg- based, privately owned company and represented by own subsidiaries in more
than 30 countries worldwide.
In cooperation with highly acclaimed international partners, Helm offers developments of generic
pharmaceuticals, IP researches, registrations of high quality e-CTD dossiers, launch and life cycle
Our global presence and extensive variety of excellent service functions mean that Helm is your ideal
partner for all stages of the product life cycle from the initial idea generation through to the launch and
supply of the medicinal product.
-High quality e-CTD dossiers per current EU-requirements and international registration strategies.
-Tailor made portfolio ideas.
- Excellent project management
- Collaborations for innovative technology platforms.
We are interested in:
- Identifying out-licensing and co-operation opportunities - especially for EU, Nordics, UK, LATAM, MENA
& CIS markets.
- Exploring product & brand acquisition opportunities in the targeted territories.
- Divestment of companies
We are NOT interested in:
- Regulatory Services
- CRO + CMO Services
Kathrin CasulaSenior Licensing Manager
Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. Since 2012, Helsinn has been coordinating clinical and regulatory activities in China from Beijing and in 2017 established an office in Shanghai to pursue commercial activities. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, and the U.S., as well as a product presence in approximately 190 countries globally.
Mr Rachid BenhamzaDirector, Head Corporate Product Management
Hovione has over 57 years of experience as a CDMO and is currently a fully integrated supplier offering from drug substance to drug product intermediate to drug product. With four FDA inspected sites in the US, China, Ireland, and Portugal, and development laboratories in Lisbon and New Jersey, the company provides branded pharmaceutical customers services for the development and compliant manufacture of innovative drugs and is able to support highly potent compounds. For generic pharmaceutical customers the company offers niche off-patent API products. In the inhalation area Hovione is the only independent company offering a complete range of services. Hovione has recently created a pharmaceutical Licensing Department identifying new indications for existing molecules. We look forward to discussing your requirements at Montreaux. Please visit visit http://www.hovione.com.